CL2018003431A1 - Tratamiento de la enfermedad de parkinson. - Google Patents

Tratamiento de la enfermedad de parkinson.

Info

Publication number
CL2018003431A1
CL2018003431A1 CL2018003431A CL2018003431A CL2018003431A1 CL 2018003431 A1 CL2018003431 A1 CL 2018003431A1 CL 2018003431 A CL2018003431 A CL 2018003431A CL 2018003431 A CL2018003431 A CL 2018003431A CL 2018003431 A1 CL2018003431 A1 CL 2018003431A1
Authority
CL
Chile
Prior art keywords
disease
parkinson
treatment
arilacetilen
hydrazide
Prior art date
Application number
CL2018003431A
Other languages
English (en)
Spanish (es)
Inventor
Nitin Krishnaji Damle
Sanjay Nandlalji Mandhane
Manoj Atmaramji Upadhya
Sameer Vishwanath Mehetre
Gajanan Uttamrao Chidrewar
Prabal Sengupta
Trinadha Rao Chitturi
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of CL2018003431A1 publication Critical patent/CL2018003431A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2018003431A 2016-06-02 2018-11-30 Tratamiento de la enfermedad de parkinson. CL2018003431A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621019185 2016-06-02
IN201621019087 2016-06-02

Publications (1)

Publication Number Publication Date
CL2018003431A1 true CL2018003431A1 (es) 2019-05-10

Family

ID=59388123

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003431A CL2018003431A1 (es) 2016-06-02 2018-11-30 Tratamiento de la enfermedad de parkinson.

Country Status (26)

Country Link
US (4) US10849887B2 (enExample)
EP (2) EP3463351B1 (enExample)
JP (1) JP6974357B2 (enExample)
KR (1) KR102508288B1 (enExample)
CN (1) CN109475539B (enExample)
AU (1) AU2017273415B2 (enExample)
CL (1) CL2018003431A1 (enExample)
CY (1) CY1125285T1 (enExample)
DK (1) DK3463351T3 (enExample)
ES (1) ES2914782T3 (enExample)
HR (1) HRP20220683T1 (enExample)
HU (1) HUE059387T2 (enExample)
IL (1) IL263188B (enExample)
LT (1) LT3463351T (enExample)
MX (1) MX385276B (enExample)
MY (1) MY193754A (enExample)
NZ (1) NZ748592A (enExample)
PH (1) PH12018502457B1 (enExample)
PL (1) PL3463351T3 (enExample)
PT (1) PT3463351T (enExample)
RS (1) RS63243B1 (enExample)
SG (1) SG11201810294QA (enExample)
SI (1) SI3463351T1 (enExample)
SM (1) SMT202200228T1 (enExample)
UA (1) UA123018C2 (enExample)
WO (1) WO2017208267A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2844256T3 (da) 2012-05-02 2023-03-27 Univ Georgetown Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer
LT3463351T (lt) * 2016-06-02 2022-06-10 Sun Pharma Advanced Research Company Limited Parkinsono ligos gydymas
CN110606840A (zh) 2018-06-15 2019-12-24 日产化学株式会社 5-炔基吡啶化合物的制造方法
CN120040470A (zh) 2018-11-20 2025-05-27 乔治敦大学 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法
EP3982964A1 (en) * 2019-06-11 2022-04-20 Sun Pharma Advanced Research Company Ltd Treatment for synucleinopathies
WO2021030783A1 (en) * 2019-08-15 2021-02-18 Duke University Compositions and methods for the treatment cancer and cns disorders
WO2022024072A1 (en) 2020-07-31 2022-02-03 Sun Pharma Advanced Research Company Limited N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl) ethynyl]-benzohydrazide for treatment of alzheimer's disease
CA3251516A1 (en) 2022-05-02 2023-11-09 Sun Pharma Advanced Research Company Limited Methods of reducing progression of neurodegenerative disease
KR20250040552A (ko) 2023-09-14 2025-03-24 주식회사 엑소스템텍 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2665709B1 (en) * 2011-01-21 2016-12-07 Sun Pharma Advanced Research Company Limited Diarylacetylene hydrazide containing tyrosine kinase inhibitors
DK2844256T3 (da) 2012-05-02 2023-03-27 Univ Georgetown Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer
CA2985161A1 (en) * 2015-05-18 2016-11-24 Sun Pharma Advanced Research Company Limited Novel amidoheteroaryl aroyl hydrazide ethynes
LT3463351T (lt) * 2016-06-02 2022-06-10 Sun Pharma Advanced Research Company Limited Parkinsono ligos gydymas

Also Published As

Publication number Publication date
PH12018502457B1 (en) 2022-01-12
US20190275017A1 (en) 2019-09-12
KR102508288B1 (ko) 2023-03-09
MY193754A (en) 2022-10-27
US20210015805A1 (en) 2021-01-21
LT3463351T (lt) 2022-06-10
EP3463351B1 (en) 2022-04-27
US20220273632A1 (en) 2022-09-01
SG11201810294QA (en) 2018-12-28
UA123018C2 (uk) 2021-02-03
US11813252B2 (en) 2023-11-14
PL3463351T3 (pl) 2022-06-20
DK3463351T3 (da) 2022-06-07
HRP20220683T1 (hr) 2022-07-08
IL263188B (en) 2021-08-31
RS63243B1 (sr) 2022-06-30
CA3024976A1 (en) 2017-12-07
CN109475539A (zh) 2019-03-15
SMT202200228T1 (it) 2022-07-21
US20240066014A1 (en) 2024-02-29
IL263188A (en) 2018-12-31
MX2018014944A (es) 2019-03-07
MX385276B (es) 2025-03-18
CN109475539B (zh) 2021-12-28
KR20190015257A (ko) 2019-02-13
US10849887B2 (en) 2020-12-01
AU2017273415A1 (en) 2018-12-06
CY1125285T1 (el) 2025-03-28
BR112018074439A2 (pt) 2019-03-06
PH12018502457A1 (en) 2019-10-21
JP6974357B2 (ja) 2021-12-01
HUE059387T2 (hu) 2022-11-28
US11583522B2 (en) 2023-02-21
ES2914782T3 (es) 2022-06-16
SI3463351T1 (sl) 2022-07-29
JP2019520344A (ja) 2019-07-18
AU2017273415B2 (en) 2023-01-19
NZ748592A (en) 2025-11-28
EP3463351A1 (en) 2019-04-10
PT3463351T (pt) 2022-06-02
WO2017208267A1 (en) 2017-12-07
EP4085912A1 (en) 2022-11-09

Similar Documents

Publication Publication Date Title
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
MX391812B (es) Agonista fxr derivado de esteroides.
MX389672B (es) Inhibidores de ssao de aminopirimidina
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
BR112017002001A2 (pt) compostos e composição farmacêutica
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
MX373373B (es) Inhibidores de desmetilasa-1 específica de lisina.
EA201990400A1 (ru) Соединения и композиции и их применение
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
MX2022006768A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
EA202090414A1 (ru) Соединения и их применение
MX378739B (es) Compuestos de 2-oxindol.
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
IL260009B (en) Novel bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease
BR112018012701A2 (pt) novos compostos de 1,2,3 triazol-tiazol, processo para preparação e utilização dos mesmos